Platinum-Based Chemotherapy: Clinical Uses, Efficacy and Side Effects

$230.00

Kulmira Nurgali, PhD – Associate Professor, College of Health and Biomedicine, Institute for Health and Sport, Victoria University, Australia; Honorary Associate Professor, Department of Medicine, University of Melbourne, Australia; Head of the Enteric Neuropathy Laboratory, Centre for Health, Research & Education, Sunshine Hospital, Melbourne, Australia; Director, Stem Cells and Regenerative Medicine Program, Australian Institute for Musculoskeletal Science
Raquel Abalo Delgado, PhD – Full Professor, Department of Pharmacology and Nutrition, Universidad Rey Juan Carlos, Madrid, Spain

Series: Cancer Etiology, Diagnosis and Treatments
BISAC: MED012000; MED062000
DOI: https://doi.org/10.52305/MPSL2859

According to the Global Cancer Observatory, in 2020 the number of new cases of cancer was 19.3 million people in the whole world, with breast, lung, and colorectal cancer comprising 10-11% each of these figures. In the same year, there were almost 10 million deaths from cancer, with lung cancer being the one leading to more deaths (18%). Unfortunately, these figures are only expected to increase, with an estimated incidence of 30.2 million cases in 2040. Thus, cancer is a worldwide public health priority, with a high socio-economic impact.

Chemotherapy stands out among the available cancer treatments. Platinum-based chemotherapy is one of the earliest chemotherapeutics introduced to the clinics and it is still the first-line treatment, used alone or in combination with other anti-neoplastic therapy and/or radiation, for many types of cancer in both adults and children. The book Platinum-Based Chemotherapy: Clinical Uses, Efficacy and Side Effects offers the reader a general overview of this therapy, as well as an update on some of the most relevant issues specific to this therapy.

Table of Contents

Preface

Chapter 1. Platinum Analogs from a Chemical and Biological Point of View
Mauricio A. Retamal1,2,3, Ignacio A. Cortés-Fuentes4,5, Juan G. Gormaz6 and Paola R. Campodónico7
1
Universidad del Desarrollo, Programa de Comunicación Celular en Cáncer, Clínica Alemana Facultad de Medicina, Santiago, Chile
2Universidad del Desarrollo, Centro de Fisiología Celular e Integrativa, Clínica Alemana Facultad de Medicina, Santiago, Chile
3Department of Cell Physiology and Molecular Biophysics, and Center for Membrane Protein Research, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA
4Hospital Barros Luco-Trudeau, San Miguel, Santiago, Chile
5Departamento de Otorrinolaringología, Facultad de Medicina, Universidad de Chile, Santiago, Chile
6Facultad de Medicina, Universidad de Chile, Santiago, Chile
7Universidad del Desarrollo, Facultad de Medicina, Instituto de Ciencias e Innovación en Medicina, Centro de Química Médica, Clínica Alemana Universidad del Desarrollo, Santiago, Chile

Chapter 2. Role of Cellular Senescence in Resistance to Platinum-Based Chemotherapy
Aleksandra Olszewska1,2, Monika Granica1,3,, Aleksandra Klemba1,4, Claudine Kieda1 and Halina Was1
1Laboratory of Molecular Oncology and Innovative Therapies, Military Institute of Medicine, Warsaw, Poland
2Postgraduate School of Molecular Medicine, Medical University of Warsaw, Warsaw, Poland
3Doctoral School of Translational Medicine, Centre of Postgraduate Medical Education, Warsaw, Poland
4College of Inter-Faculty Individual Studies in Mathematics and Natural Sciences, University of Warsaw, Warsaw, Poland

Chapter 3. Main Mechanisms Involved in Major and Minor Side Effects Triggered by Cisplatin-Based Therapy
Mauricio Burotto1, Ignacio A. Cortés-Fuentes2,3, Jaime Gonzalez-Montero1,4 and Juan G. Gormaz5
1Bradford Hill, Clinical Research Center, Santiago, Chile
2Hospital Barros Luco-Trudeau, San Miguel, Santiago, Chile
3Departamento de Otorrinolaringología, Facultad de Medicina, Universidad de Chile, Chile
4Departamento de Oncología básico-clínico, Universidad de Chile, Chile
5Facultad de Medicina, Universidad de Chile, Chile

Chapter 4. Peripheral Neuropathy and Cognitive Impairment Caused by Platinum-Based Chemotherapy
Hannah R. Wardill1,2, Ysabella Z. A. Van Sebille3, Nadeen T. Ali4 and Lisa B. Grech5
1
Supportive Oncology Research Group, School of Biomedicine, The University of Adelaide, Australia
2Supportive Oncology Research Group, Precision Medicine (Cancer), South Australian Health and Medical Research Institute, Australia
3Division of Health Sciences, University of South Australia, Australia
4Faculty of Pharmacy, Al-Yyarmouk College, Khartoum, Sudan
5Medicine Monash Health, Monash University, Australia

Chapter 5. Ototoxicity Induced by Platinum-Based Chemotherapy
Ignacio A. Cortés-Fuentes1,2, Mauricio Retamal Lucero3,4,5 and Juan G. Gormaz6
1
Hospital Barros Luco-Trudeau, San Miguel, Santiago, Chile
2Departamento de Otorrinolaringología, Facultad de Medicina, Universidad de Chile, Chile
3Universidad del Desarrollo, Programa de Comunicación Celular en Cáncer. Clínica Alemana Facultad de Medicina. Santiago, Chile
4Universidad del Desarrollo, Centro de Fisiología Celular e Integrativa. Clínica Alemana Facultad de Medicina. Santiago, Chile
5Department of Cell Physiology and Molecular Biophysics, and Center for Membrane Protein Research, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, United States
6Facultad de Medicina, Universidad de Chile, Chile

Chapter 6. Cardiovascular Side Effects of Platinum-Based Chemotherapy
Kristen Renee McSweeney, Laura Kate Gadanec and Anthony Zulli
Institute for Health and Sport, Victoria University, Melbourne, Victoria, Australia

Chapter 7. Gastrointestinal Side Effects of Platinum-Based and Other Chemotherapeutic Drugs
Petra Semenye1, Rachel McQuade2,3, Raquel Abalo4,5,6,7 and Kulmira Nurgali1,2,8,
1Institute for Health and Sport, Victoria University, Melbourne, Australia
2Department of Medicine Western Health, The University of Melbourne, Melbourne, Australia
3Florey Institute of Neuroscience and Mental Health, Melbourne, Australia
4Area of Pharmacology and Nutrition, Department of Basic Health Sciences, Faculty of Health Sciences, Universidad Rey Juan Carlos, Alcorcón, Madrid, Spain
5High Performance Research Group in Physiopathology and Pharmacology of the Digestive System (NeuGut-URJC), Universidad Rey Juan Carlos, Alcorcón, Madrid, Spain
6Associated Unit to Institute of Medicinal Chemistry (Unidad Asociada I+D+i del Instituto de Química Médica, IQM), Spanish National Research Council (CSIC), Madrid, Spain
7Working Group of Basic Sciences in Pain and Analgesia of the Spanish Pain Society, Madrid, Spain
8Regenerative Medicine and Stem Cells Program, Australian Institute of Musculoskeletal Science (AIMSS), Melbourne, Australia

Index


Editor’s ORCID iD

Kulmira Nurgalihttps://orcid.org/0000-0002-2597-6929
Raquel Abalo Delgado – https://orcid.org/0000-0002-6726-8795